Joe Stephenson

3.1k citations

65 papers · 2.0k indexed · h-index 25

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism

Papers in

Oncology 41
- Colorectal Cancer Treatments and Studies 12
- Cancer Treatment and Pharmacology 9
- Pancreatic and Hepatic Oncology Research 6
- HER2/EGFR in Cancer Research 5
Hematology 8

Co-authors: John Nemunaitis Donald Richards Lainie P. Martin John S. Hill Benny Amore Elwyn Loh Erik Rasmussen Kyriakos P. Papadopoulos
Journals: Journal of Clinical Oncology (19 papers)Investigational New Drugs (5 papers)Cancer Chemotherapy and Pharmacology (4 papers)Clinical Cancer Research (3 papers)Journal of Thoracic Oncology (3 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Joe Stephenson

63 papers receiving 2.0k citations

Peers

Countries citing papers authored by Joe Stephenson

Since Specialization

Citations

This map shows the geographic impact of Joe Stephenson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joe Stephenson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joe Stephenson more than expected).

Fields of papers citing papers by Joe Stephenson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joe Stephenson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joe Stephenson. The network helps show where Joe Stephenson may publish in the future.

Co-authors

The 25 scholars most cited alongside Joe Stephenson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joe Stephenson Line = papers co-authored together Joe Stephenson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301). Journal of Clinical Oncology* ·Georgina V. Long, Victoria Atkinson, Paolo A. Ascierto, Diwakar Davar, Omid Hamid, Caroline Robert, Marcus O. Butler, Reinhard Dummer, Christine Häfner, Muhammad Adnan Khattak, James Larkin, Paul Lorigan, Meredith McKean, Menna Abaye, Heather M. Shaw, Joe Stephenson, Yuan Yuan, W.Y. Jamie Lau, Piruntha Thiyagarajah, Dirk Schadendorf	2024	3
2	A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma Cancer Chemotherapy and Pharmacology ·Tracy Murray Stewart, Daniel D. Von Hoff, Michael L. Fitzgerald, Laurence J. Marton, Vanesia Amelia Sebayang, Thomas E. Boyd, Paul Conkling, Lawrence Garbo, Robert M. Jotte, Donald Richards, David A. Smith, Joe Stephenson, Nicholas J. Vogelzang, Н К Козлова, Robert A. Casero	2020	15
3	First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Kyriakos P. Papadopoulos, Maxim Baltin, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny Amore, Dirk Nagorsen, John S. Hill, Joe Stephenson	2017	157
4	An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC) Lung Cancer ·Mark M. Awad, Kou Jun-l, Leena Gandhi, Joe Stephenson, Ramaswamy Govindan, Daniel S. Bradford, Philip Bonomi, David M. Ellison, Keith D. Eaton, Holger Fritsch, Gerd Munzert, Bruce E. Johnson, Mark A. Socinski	2016	47
5	A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer Clinical Cancer Research ·Alex A. Adjei, Donald Richards, Anthony B. El-Khoueiry, Fadi Braiteh, Vanesia Amelia Sebayang, Joe Stephenson, Aram F. Hezel, Morris Sherman, Lawrence Garbo, 刘曦子, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li‐Tain Yeh, Mingxia Gui, David M. Wilson, Kimberly J. Manhard, Prabhu Rajagopalan, Heiko Krissel, Neil J. Clendeninn	2015	16
6	Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer Cancer Chemotherapy and Pharmacology ·Niall C. Tebbutt, Dusan Kotasek, Howard A. Burris, Lee S. Schwartzberg, Herbert I. Hurwitz, Joe Stephenson, Douglas Warner, Lisa Chen, Cheng‐Pang Hsu, David Goldstein	2015	9
7	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero	2014	92
8	An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors Investigational New Drugs ·Robert M. Jotte, Daniel D. Von Hoff, Fadi Braiteh, Carlos Becerra, Donald Richards, David A. Smith, Lawrence Garbo, Joe Stephenson, Paul Conkling, Jean Chevrel, Jian Chen, P. Kellie Turner, Kay Hoong Chow, Vinh Gia Vuong, Robert Ilaria	2014	10
9	Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients Clinical Pharmacology in Drug Development ·Kevin M. Koch, Young‐Hyuck Im, Sung‐Bae Kim, Anastasiya S. Tabalina, Joe Stephenson, Jeffrey Botbyl, Leanne Cartee, Kono Hiromi, Derry Ridgway	2013	23
10	A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Elisabeth I. Heath, Jeffrey R. Infante, Lionel D. Lewis, Thehang Luu, Joe Stephenson, Antoinette R. Tan, 辰雄西成, Patricia LoRusso, Bo Ma, A. Benjamin Suttle, Joseph F. Kleha, Howard Ball, Mohammed M. Dar	2013	29
11	Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer Lung Cancer ·Joe Stephenson, John Nemunaitis, Anil A. Joy, Julie Martin, Ying‐Ming Jou, Da Zhang, Paul Statkevich, Siu‐Long Yao, Yali Zhu, Haiyu Zhou, Karen Small, Rajat Bannerji, Martin J. Edelman	2013	81
12	Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer The Prostate ·Donald L. Trump, Heather Payne, Kurt Miller, Johann S. de Bono, Joe Stephenson, Howard A. Burris, Faith E. Nathan, Maria Taboada, Thomas Morris, Andreas Hübner	2011	16
13	A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma Molecular Therapy ·Tae-Ho Hwang, Anne Moon, James M. Burke, Antoni Ribas, Joe Stephenson, Caroline J. Breitbach, Manijeh Daneshmand, Naomi De Silva, Kelley A. Parato, Jean‐Simon Diallo, Yeon-Sook Lee, Ta‐Chiang Liu, John C. Bell, David H. Kirn	2011	122
14	A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy Investigational New Drugs ·Ramesh K. Ramanathan, Joe Stephenson, Glen J. Weiss, Linda Pestano, Ann M. Lowe, Rainer Hoefgen, Broadway Rt, Julie Martin, Lynn Kirkpatrick, Donald Richards	2011	32
15	A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer Clinical Colorectal Cancer ·Shivaani Kummar, Mehmet Sitki Copur, Michal G. Rose, Scott Wadler, Joe Stephenson, Mark Allen O’Rourke, Wayne D. Brenckman, Robert D. Tilton, Shwu-Huey Liu, Zaoli Jiang, Robert T. Singkoh, Yung-Chi Cheng, Edward Chu	2011	89
16	A phase 1‐2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma Cancer ·Jeffrey S. Weber, Wolfram E. Samlowski, René González, Antoni Ribas, Joe Stephenson, Steven O’Day, Takami Sato, Robert T. Dorr, Qodirova Dilnoza Xoliq qizi Shabatova Rabig'a Janasbay qizi Valijonova Nafosatxon, Evan M. Hersh	2010	13
17	Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma BMC Cancer ·C. Vecchyo Calcáneo, Casey Cunningham, Neil Senzer, Joe Stephenson, Stephen P. Anthony, Steven O’Day, Gary Frenette, Anna C. Pavlick, Barry Jones, M. J. Uprichard, John Nemunaitis	2009	70
18	P3-138: A Phase I open label study of continuous oral treatment with BIBF 1120 together with carboplatin and paclitaxel treated patients with non–small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·D. Ross Camidge, Paul Conkling, Joe Stephenson, Д. А. Шапиро	2007	9
19	PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·George R. Blumenschein, Alan Sandler, Timothy J. O’Rourke, Jesse McGreivy, Yu‐Nien Sun, Yining Ye, 守和宮之原, Joe Stephenson	2007	7
20	A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL) Biology of Blood and Marrow Transplantation ·John G. Gribben, Nancy L. Bartlett, Joe Stephenson, Michael S. Milder, Ralph V. Boccia, Charles H. Redfern, 刘登东, Ronald Berenson, Mark W. Frohlich	2005	1

About Joe Stephenson

Joe Stephenson is a scholar working on Oncology, Hematology, Pulmonary and Respiratory Medicine, Genetics and Biotechnology, having authored 65 papers that have together received 2.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (8 papers), Prostate Cancer Treatment and Research (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Research and Treatments (5 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (360 citations), Immunology (429 citations), Pulmonary and Respiratory Medicine (488 citations) and Molecular Biology (894 citations). Joe Stephenson has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include John Nemunaitis, Donald Richards, Lainie P. Martin, John S. Hill, Benny Amore, Elwyn Loh, Erik Rasmussen, Kyriakos P. Papadopoulos, Anthony J. Olszanski and Dirk Nagorsen. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Cancer Chemotherapy and Pharmacology, Clinical Cancer Research and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact